COMETRIQ® (cabozantinib) is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC).
COMETRIQ® inhibits the activity of tyrosine kinases, including RET; MET; and VEGFR-1, -2, and -3. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and maintenance of the tumor microenvironment.
COMETRIQ® is exclusively distributed by Diplomat Specialty Pharmacy, which may be contacted at:
Learn more about Exelixis® Access Services, a unique program that provides information on MTC patient access to COMETRIQ®, reimbursement support, and financial assistance.